Stock profile

Tien Liang BioTech Co., Ltd.(4127.TWO)

Country: TaiwanSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: TWO
P/E TTM
584.5
History
P/E NTM
N/A
Market cap
3.48B
Currency TWD
KvantraRankiN/ANot enough data to calculate KvantraRank
Value31
Quality34
MomentumN/A
Current price
83.00-6.74%
Benchmarks

No price history available.

Key financial summary

Financials in TWD
202020212022202320242025TTM2026E
Total revenueTWDm431571529460385512593N/A
Operating profitTWDmLockedLockedLockedLockedLockedLockedLockedLocked
Net profitTWDm-5247591812-106N/A
EPS reportedTWDLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareTWDLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareTWDLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareTWDLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowTWDmLockedLockedLockedLockedLockedLockedLockedLocked
Net debtTWDmLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityTWDmLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareTWDLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)TWDLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in TWD
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. The company's offerings include traditional Chinese medicine (TCM) formulations, predominantly in pill form. These remedies address a broad spectrum of conditions, such as internal organ deficiencies (e.g., liver and kidney), various forms of musculoskeletal and neuropathic discomfort (including low back pain, joint pain, rheumatism, gout, and neuralgia), and common ailments like dizziness, digestive issues (constipation, hemorrhoids), respiratory symptoms (colds, bronchitis, coughs), and skin conditions (athlete's foot). Additionally, Tien Liang BioTech provides a range of Western pharmaceutical products. This segment features topical applications like ointments, pain relief gels, soreness sprays, and transdermal pain patches, alongside oral preparations such as tablets and capsules. The portfolio also includes specialized items like hair removal creams. Beyond pharmaceuticals, the company extends its reach into general consumer health and personal care. These offerings comprise products designed for body relaxation and comfort, items to alleviate post-exercise discomfort, oral hygiene products, and various soaps.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryTaiwan
Trades inTWD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Tien Liang BioTech Co., Ltd. (4127.TWO)

4127.TWO · TWO · Healthcare
83.00-6.74%
Sign up to track this stock

No price history available.

KvantraRankN/A
P/E TTM584.5
P/E NTMN/A
Market cap3.48B
KvantraRank?

Not enough data to calculate KvantraRank

Financialsin TWD
20242025TTM2026E
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. The company's offerings include traditional Chinese medicine (TCM) formulations, predominantly in pill form. These remedies address a broad spectrum of conditions, such as internal organ deficiencies (e.g., liver and kidney), various forms of musculoskeletal and neuropathic discomfort (including low back pain, joint pain, rheumatism, gout, and neuralgia), and common ailments like dizziness, digestive issues (constipation, hemorrhoids), respiratory symptoms (colds, bronchitis, coughs), and skin conditions (athlete's foot). Additionally, Tien Liang BioTech provides a range of Western pharmaceutical products. This segment features topical applications like ointments, pain relief gels, soreness sprays, and transdermal pain patches, alongside oral preparations such as tablets and capsules. The portfolio also includes specialized items like hair removal creams. Beyond pharmaceuticals, the company extends its reach into general consumer health and personal care. These offerings comprise products designed for body relaxation and comfort, items to alleviate post-exercise discomfort, oral hygiene products, and various soaps.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryTaiwan
Trades inTWD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans
Tien Liang BioTech Co., Ltd. (4127.TWO) KvantraRank & Stock Analysis | Kvantra